Wei Shuo, Kashiwagi Masahide, Kota Smitha, Xie Zhihong, Nagase Hideaki, Brew Keith
Department of Biomedical Science, Florida Atlantic University, Boca Raton, Florida 33431, USA.
J Biol Chem. 2005 Sep 23;280(38):32877-82. doi: 10.1074/jbc.C500220200. Epub 2005 Aug 3.
Tissue inhibitor of metalloproteinase-3 (TIMP-3) is a dual inhibitor of the matrix metalloproteinases (MMPs) and some adamalysins, two families of extracellular and cell surface metalloproteinases that function in extracellular matrix turnover and the shedding of cell surface proteins. The mechanism of inhibition of MMPs by TIMPs has been well characterized, and since the catalytic domains of MMPs and adamalysins are homologous, it was assumed that the interaction of TIMP-3 with adamalysins is closely similar. Here we report that the inhibition of the extracellular region of ADAM-17 (tumor necrosis factor alpha-converting enzyme (TACE)) by the inhibitory domain of TIMP-3 (N-TIMP-3) shows positive cooperativity. Also, mutations in the core of the MMP interaction surface of N-TIMP-3 dramatically reduce the binding affinity for MMPs but have little effect on the inhibitory activity for TACE. These results suggest that the mechanism of inhibition of ADAM-17 by TIMP-3 may be distinct from that for MMPs. The mutant proteins are also effective inhibitors of tumor necrosis factor alpha (TNF-alpha) release from phorbol ester-stimulated cells, indicating that they provide a lead for engineering TACE-specific inhibitors that may reduce side effects arising from MMP inhibition and are possibly useful for treatment of diseases associated with excessive TNF-alpha levels such as rheumatoid arthritis.
金属蛋白酶组织抑制剂-3(TIMP-3)是基质金属蛋白酶(MMPs)和一些解聚素的双重抑制剂,这两类细胞外和细胞表面金属蛋白酶在细胞外基质周转以及细胞表面蛋白的脱落过程中发挥作用。TIMP对MMPs的抑制机制已得到充分表征,并且由于MMPs和解聚素的催化结构域具有同源性,因此推测TIMP-3与解聚素的相互作用非常相似。在此我们报告,TIMP-3的抑制结构域(N-TIMP-3)对ADAM-17(肿瘤坏死因子α转换酶(TACE))细胞外区域的抑制表现出正协同性。此外,N-TIMP-3的MMP相互作用表面核心区域的突变显著降低了对MMPs的结合亲和力,但对TACE的抑制活性影响很小。这些结果表明,TIMP-3对ADAM-17的抑制机制可能与对MMPs的抑制机制不同。这些突变蛋白也是佛波酯刺激细胞释放肿瘤坏死因子α(TNF-α)的有效抑制剂,这表明它们为设计TACE特异性抑制剂提供了线索,这种抑制剂可能会减少因抑制MMPs而产生的副作用,并且可能对治疗与TNF-α水平过高相关的疾病(如类风湿性关节炎)有用。